Novo Nordisk will unveil 11 abstracts containing safety and efficacy data from its haemophilia portfolio and pipeline at the 56th Annual Meeting of the American Society of Hematology (ASH), which will be held December 6–9 in San Francisco, California.

Following is a selection of the abstracts that will be presented:

Changes in annualised bleeding rate over time and relationship with dosing of turoctocog alfa during the guardian programme (Poster Number: 2850), Safety, efficacy, and pharmacokinetics of nonacog beta pegol (N9-GP) in prophylaxis and treatment of bleeding episodes in previously treated pediatric haemophilia B patients (Poster Number: 1513), Safety and efficacy of nonacog beta pegol (N9-GP) for prophylaxis and treatment of bleeding episodes in previously treated patients with haemophilia B: Results from an extension trial (Poster Number: 2846) Impact of Glanzmann's Thrombasthenia: Perceptions from US patients and parents (Poster Number: 4853)..   Unmet needs in diagnosis and treatment of Glanzmann's Thrombasthenia: Perceptions of US hematologists and nurses (Poster Number: 2179)A complete listing of abstracts being presented and published at ASH can be accessed here.

"Novo Nordisk is excited to present such a robust data set at this year's ASH Annual Meeting and to continue to make important contributions to the body of scientific knowledge available on haemophilia and other rare bleeding disorders," said Stephanie Seremetis, MD, CMO and CVP, Haemophilia, Novo Nordisk. "We seek to continuously advance the development of new therapies to benefit the bleeding disorders community."

Indications and Usage for Novoeight (Antihemophilic Factor [Recombinant])Novoeight is an injectable medicine used to control and prevent bleeding in people with haemophilia A. Your healthcare provider may give you Novoeight when you have surgery. Novoeight is not used to treat von Willebrand Disease.